IC
LRMR icon

Ikarian Capital’s Larimar Therapeutics LRMR Stock Holding History

Ikarian Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-58,526
Closed -$126K – 170
2025
Q1 		$126K Hold
58,526
– – 0.02% 149
2024
Q4 		$226K Sell
58,526
-2
-0% -$13 0.03% 148
2024
Q3 		$383K Sell
58,528
-265,000
-82% -$2.13M 0.05% 122
2024
Q2 		$2.35M Sell
323,528
-115,000
-26% -$881K 0.41% 52
2024
Q1 		$3.33M Sell
438,528
-164,340
-27% -$1.28M 0.36% 67
2023
Q4 		$2.74M Sell
602,868
-80,000
-12% -$270K 0.26% 77
2023
Q3 		$2.7M Buy
+682,868
New +$2.58M 0.32% 70
2022
Q3 		– Sell
-51,606
Closed -$100K – 141
2022
Q2 		$100K Hold
51,606
– – 0.02% 130
2022
Q1 		$209K Buy
51,606
+4,413
+9% +$28.9K 0.03% 164
2021
Q4 		$510K Hold
47,193
– – 0.08% 126
2021
Q3 		$545K Sell
47,193
-5,775
-11% -$69.3K 0.04% 182
2021
Q2 		$520K Sell
52,968
-372,416
-88% -$4.21M 0.04% 186
2021
Q1 		$6.21M Buy
+425,384
New +$7.73M 0.21% 107

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ikarian Capital's LRMR Position: Q2 2025 in Review

Ikarian Capital sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 58,526 shares — an estimated $126K sold.

Ikarian Capital first reported a position in LRMR in Q1 2021 and held it in 13 quarters. The position peaked at $6.21M in Q1 2021. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

  • Ikarian Capital reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 58,526 Larimar Therapeutics shares in Q2 2025, an estimated $126K.
  • Ikarian Capital first reported a position in Larimar Therapeutics in Q1 2021 and held it in 13 quarters.
  • Ikarian Capital's Larimar Therapeutics position peaked at $6.21M in Q1 2021.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.